WO2021049850A3 - 혈관신생억제 및 저산소환경에 의해 활성화되는 항암 치료진단제 - Google Patents

혈관신생억제 및 저산소환경에 의해 활성화되는 항암 치료진단제 Download PDF

Info

Publication number
WO2021049850A3
WO2021049850A3 PCT/KR2020/012111 KR2020012111W WO2021049850A3 WO 2021049850 A3 WO2021049850 A3 WO 2021049850A3 KR 2020012111 W KR2020012111 W KR 2020012111W WO 2021049850 A3 WO2021049850 A3 WO 2021049850A3
Authority
WO
WIPO (PCT)
Prior art keywords
anticancer
angiogenesis
theranostic agent
hypoxic environment
agent activated
Prior art date
Application number
PCT/KR2020/012111
Other languages
English (en)
French (fr)
Other versions
WO2021049850A2 (ko
Inventor
김종승
김형석
한지유
샤르마아밋
임문수
Original Assignee
고려대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고려대학교 산학협력단 filed Critical 고려대학교 산학협력단
Publication of WO2021049850A2 publication Critical patent/WO2021049850A2/ko
Publication of WO2021049850A3 publication Critical patent/WO2021049850A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

본 발명은 혈관신생억제 및 저산소환경에 의해 활성화되는 항암 치료진단제에 관한 것이다. 본 발명에 따른 항암 치료진단제는 COX-2 억제를 통해 항-혈관신생 효과를 나타낼 뿐만 아니라 저산소증에서 향상된 약물 활성을 나타내는바, 종양 표적화, 진단 및 종양 부위로의 전구체 약물 전달을 효과적으로 달성할 수 있다.
PCT/KR2020/012111 2019-09-10 2020-09-08 혈관신생억제 및 저산소환경에 의해 활성화되는 항암 치료진단제 WO2021049850A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0112020 2019-09-10
KR1020190112020A KR102276692B1 (ko) 2019-09-10 2019-09-10 혈관신생억제 및 저산소환경에 의해 활성화되는 항암 치료진단제

Publications (2)

Publication Number Publication Date
WO2021049850A2 WO2021049850A2 (ko) 2021-03-18
WO2021049850A3 true WO2021049850A3 (ko) 2021-05-06

Family

ID=74866669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/012111 WO2021049850A2 (ko) 2019-09-10 2020-09-08 혈관신생억제 및 저산소환경에 의해 활성화되는 항암 치료진단제

Country Status (2)

Country Link
KR (1) KR102276692B1 (ko)
WO (1) WO2021049850A2 (ko)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180091220A (ko) * 2017-02-06 2018-08-16 고려대학교 산학협력단 인도메타신 유도 약물 전달 접합체를 포함하는 암 표적용 약물 전달 시스템
KR101990214B1 (ko) * 2017-12-12 2019-06-17 고려대학교 산학협력단 표적 특이적 항암 약물전구체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180091220A (ko) * 2017-02-06 2018-08-16 고려대학교 산학협력단 인도메타신 유도 약물 전달 접합체를 포함하는 암 표적용 약물 전달 시스템
KR101990214B1 (ko) * 2017-12-12 2019-06-17 고려대학교 산학협력단 표적 특이적 항암 약물전구체

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KIM HYEONG SEOK, SHARMA AMIT, REN WEN XIU, HAN JIYOU, KIM JONG SEUNG: "COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 185, 1 December 2018 (2018-12-01), AMSTERDAM, NL, pages 63 - 72, XP055808328, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2018.09.006 *
KUMAR RAJESH; KIM EUN-JOONG; HAN JIYOU; LEE HYUNSEUNG; SHIN WEON SUP; KIM HYUN MIN; BHUNIYA SANKARPRASAD; KIM JONG SEUNG; HONG KWA: "Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 104, 14 July 2016 (2016-07-14), AMSTERDAM, NL, pages 119 - 128, XP029681211, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2016.07.010 *
SHARMA AMIT, ARAMBULA JONATHAN F., KOO SEYOUNG, KUMAR RAJESH, SINGH HARDEV, SESSLER JONATHAN L., KIM JONG SEUNG: "Hypoxia-targeted drug delivery", CHEMICAL SOCIETY REVIEWS, ROYAL SOCIETY OF CHEMISTRY, UK, vol. 48, no. 3, 7 February 2019 (2019-02-07), UK, pages 771 - 813, XP055808234, ISSN: 0306-0012, DOI: 10.1039/C8CS00304A *
ZHOU YING; MAITI MRINMOY; SHARMA AMIT; WON MIAE; YU LE; MIAO LAN XI; SHIN JINWOO; PODDER ARUP; BOBBA KONDAPA NAIDU; HAN JIYOU; BHU: "Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 288, 28 August 2018 (2018-08-28), AMSTERDAM, NL, pages 14 - 22, XP085494606, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2018.08.036 *

Also Published As

Publication number Publication date
WO2021049850A2 (ko) 2021-03-18
KR102276692B1 (ko) 2021-07-12
KR20210030641A (ko) 2021-03-18

Similar Documents

Publication Publication Date Title
NZ749218A (en) Androgen receptor modulator and uses thereof
MX345953B (es) Usos de inmunoconjugados dirigidos a cd138.
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
WO2011098611A3 (en) Targeted alpha- particle emitting complexes comprising thorium radionuclide hydroxypyridinone containing ligand
MX2020012924A (es) Terapias combinadas de coenzima q10 para el tratamiento de cancer.
WO2014167126A3 (en) Platform for targeted delivery to stem cells and tumor cells and uses thereof
AU2018273988A1 (en) Chemoembolization agents
WO2014160216A3 (en) Dual targeting anticancer agents
GB2538023A (en) Targeted drug conjugates
CL2019002871A1 (es) Terapia combinada para cáncer de próstata.
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
NZ702242A (en) Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
PH12016501407A1 (en) Treatment of neoplasia
WO2011088456A3 (en) Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
WO2013131089A3 (en) Potent anticancer activity via dual compound activation
WO2012053768A3 (en) Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient
WO2021049850A3 (ko) 혈관신생억제 및 저산소환경에 의해 활성화되는 항암 치료진단제
AU2018244925A1 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
NZ592077A (en) Use of ammonium chloride in therapy
TW201613651A (en) Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivative
MX2022014005A (es) Formulaciones farmaceuticas de acetato de abiraterona y niraparib.
WO2018236090A3 (ko) 키토산-플루로닉 복합체 및 이를 포함하는 나노운반체
WO2015081117A3 (en) Therapeutic metal complexes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20864189

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20864189

Country of ref document: EP

Kind code of ref document: A2